Table 2.
Summary of basic data of ADEs of Smegallutide
| Characteristics | Faers n | Number of subcutaneous cases | Number of oral cases |
|---|---|---|---|
| Total number of cases | 1733 | 1541(88.92) | 192(11.08) |
| Sex | |||
| Female(%) | 1087(62.72) | 977(63.40) | 110(57.29) |
| Male(%) | 580(33.47) | 508(32.97) | 72(37.50) |
| Not Specified(%) | 66(3.81) | 56(3.63) | 10(5.21) |
| Age | |||
| 18(%) | 0(0.00) | 0(0.00) | 0(0.00) |
| 18–44(%) | 78(4.50) | 74(4.80) | 4(2.08) |
| 45–64(%) | 383(22.10) | 337(21.87) | 46(23.96) |
| 65–74(%) | 312(18.00) | 277(17.98) | 35(18.23) |
| ⩾75(%) | 132(7.62) | 119(7.72) | 13(6.77) |
| NotSpecified(%) | 828(47.78) | 734(47.63) | 94(48.96) |
| Year | |||
| 2018(%) | 35(2.02) | 35(2.27) | 0(0.00) |
| 2019(%) | 115(6.64) | 115(7.46) | 0(0.00) |
| 2020(%) | 170(9.81) | 156(10.12) | 14(7.29) |
| 2021(%) | 208(12.00) | 160(10.38) | 48(25.00) |
| 2022(%) | 308(17.77) | 253(16.42) | 55(28.65) |
| 2023(%) | 333(19.22) | 299(19.40) | 34(17.71) |
| 2024(%) | 564(32.54) | 523(33.94) | 41(21.35) |
| Reporter | |||
| Consumer(%) | 1193(68.84) | 1097(71.19) | 96(50.00) |
| Not Specified(%) | 1(0.06) | 1(0.06) | 0(0.00) |
| Other health-professional(%) | 28(1.62) | 28(1.82) | 0(0.00) |
| Pharmacist(%) | 210(12.12) | 161(10.45) | 49(25.52) |
| Physician(%) | 301(17.37) | 254(16.48) | 47(24.48) |
| Country | |||
| USA(%) | 1584(91.40) | 1421(92.21) | 163(84.90) |
| United Kiongdom(%) | 16(0.92) | 9(0.58) | 7(3.65) |
| Denmark(%) | 24(1.38) | 24(1.56) | 0(0.00) |
| Canada(%) | 16(0.92) | 16(1.04) | 0(0.00) |
| France(%) | 13(0.75) | 13(0.84) | 0(0.00) |
| Japan(%) | 6(0.35) | 0(0.00) | 6(3.13) |
| Netherlands(%) | 2(0.12) | 0(0.00) | 2(1.04) |
| Latvia(%) | 2(0.12) | 0(0.00) | 2(1.04) |